BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 28241268)

  • 1. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
    Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China.
    Chen B; Zhou M; Ouyang J; Zhou R; Xu J; Zhang Q; Yang Y; Xu Y; Shao X; Meng L; Wang J; Xu Y; Ni X; Zhang X
    Neurol Sci; 2012 Aug; 33(4):881-6. PubMed ID: 22160751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
    Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
    JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
    Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
    Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
    Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
    Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
    Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
    Ge F; Lin H; Li Z; Chang T
    Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
    Fassas A; Passweg JR; Anagnostopoulos A; Kazis A; Kozak T; Havrdova E; Carreras E; Graus F; Kashyap A; Openshaw H; Schipperus M; Deconinck E; Mancardi G; Marmont A; Hansz J; Rabusin M; Zuazu Nagore FJ; Besalduch J; Dentamaro T; Fouillard L; Hertenstein B; La Nasa G; Musso M; Papineschi F; Rowe JM; Saccardi R; Steck A; Kappos L; Gratwohl A; Tyndall A; Samijn J;
    J Neurol; 2002 Aug; 249(8):1088-97. PubMed ID: 12195460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
    JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India.
    Dayama A; Bhargava R; Kurmi SR; Jain S; Dua V
    Neurol India; 2020; 68(2):454-457. PubMed ID: 32415023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation.
    Pastelín-Martínez ML; Gallardo-Pérez MM; Gómez-de-León A; Olivares-Gazca JC; Hernández-Flores EJ; Sánchez-Bonilla D; Montes-Robles M; Robles-Nasta M; Ocaña-Ramm G; Soto-Olvera S; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Diagnosis (Berl); 2024 May; 11(2):164-170. PubMed ID: 38230519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
    Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson JE; Isaksson C; Hägglund H; Carlson K; Fagius J
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1116-21. PubMed ID: 24554104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.